What is Zacks Small Cap’s Forecast for PLX FY2025 Earnings?

Protalix BioTherapeutics, Inc. (NYSE:PLX) – Investment analysts at Zacks Small Cap decreased their FY2025 earnings per share estimates for shares of Protalix BioTherapeutics in a report released on Tuesday, March 18th. Zacks Small Cap analyst J. Vandermosten now forecasts that the company will post earnings of $0.43 per share for the year, down from their previous estimate of $0.44. The consensus estimate for Protalix BioTherapeutics’ current full-year earnings is $0.01 per share.

Other equities research analysts also recently issued research reports about the stock. HC Wainwright raised their price objective on shares of Protalix BioTherapeutics from $10.00 to $15.00 and gave the stock a “buy” rating in a research note on Monday, February 3rd. StockNews.com lowered shares of Protalix BioTherapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday.

Protalix BioTherapeutics Stock Up 5.5 %

Shares of NYSE PLX opened at $2.49 on Thursday. Protalix BioTherapeutics has a 12 month low of $0.82 and a 12 month high of $2.76. The company has a market cap of $194.30 million, a P/E ratio of -19.15 and a beta of 0.72. The business’s 50 day moving average is $2.40 and its two-hundred day moving average is $1.75.

Institutional Trading of Protalix BioTherapeutics

A number of hedge funds have recently modified their holdings of PLX. Y Intercept Hong Kong Ltd bought a new stake in shares of Protalix BioTherapeutics during the fourth quarter valued at approximately $35,000. XTX Topco Ltd bought a new stake in Protalix BioTherapeutics in the 3rd quarter valued at $36,000. Sanctuary Advisors LLC bought a new stake in Protalix BioTherapeutics in the 3rd quarter valued at $38,000. PFG Investments LLC acquired a new position in shares of Protalix BioTherapeutics in the 4th quarter valued at $39,000. Finally, Virtu Financial LLC acquired a new stake in shares of Protalix BioTherapeutics during the 3rd quarter valued at about $44,000. Institutional investors own 16.53% of the company’s stock.

About Protalix BioTherapeutics

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.